The menopause transition: signs, symptoms, and management options

N Santoro, C Roeca, BA Peters… - The Journal of Clinical …, 2021 - academic.oup.com
Context Menopause, the permanent cessation of menses, reflects oocyte depletion and loss
of gonadal steroids. It is preceded by a transition state, the perimenopause, which is …

Treating menopause—MHT and beyond

SR Davis, RJ Baber - Nature Reviews Endocrinology, 2022 - nature.com
Every woman who lives past midlife will experience menopause, which, by definition, is
complete cessation of ovarian function. This process might occur spontaneously (natural …

Drug repurposing: progress, challenges and recommendations

S Pushpakom, F Iorio, PA Eyers, KJ Escott… - Nature reviews Drug …, 2019 - nature.com
Given the high attrition rates, substantial costs and slow pace of new drug discovery and
development, repurposing of'old'drugs to treat both common and rare diseases is …

Management of menopause: a view towards prevention

RA Lobo, A Gompel - The Lancet Diabetes & Endocrinology, 2022 - thelancet.com
Women spend approximately one-third of their lives with menopause, which occurs around
50 years of age. It is now appreciated that several important metabolic and cardiovascular …

KNDy cells revisited

AM Moore, LM Coolen, DT Porter, RL Goodman… - …, 2018 - academic.oup.com
In the past decade since kisspeptin/neurokinin B/dynorphin (KNDy) cells were first identified
in the mammalian hypothalamus, a plethora of new research has emerged adding insights …

Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial

H Depypere, D Timmerman, G Donders… - The Journal of …, 2019 - academic.oup.com
Context The thermoregulatory center in the hypothalamus is stimulated by neurokinin 3
receptor (NK3R) activation and inhibited by estrogen-negative feedback. This balance is …

[HTML][HTML] A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms …

GL Fraser, S Lederman, A Waldbaum, R Kroll… - Menopause, 2020 - journals.lww.com
Objective: Menopausal vasomotor symptoms (VMS) may result from altered
thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing …

[HTML][HTML] Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial

JK Prague, RE Roberts, AN Comninos, S Clarke… - The Lancet, 2017 - thelancet.com
Background Hot flushes affect 70% of menopausal women and often severely impact
physical, psychosocial, sexual, and overall wellbeing. Hormone replacement therapy is …

Mechanisms in endocrinology: estradiol as a male hormone

N Russell, M Grossmann - European Journal of Endocrinology, 2019 - academic.oup.com
Evidence has been accumulating that, in men, some of the biological actions traditionally
attributed to testosterone acting via the androgen receptor may in fact be dependent on its …

The emerging therapeutic potential of kisspeptin and neurokinin B

B Patel, K Koysombat, EG Mills, J Tsoutsouki… - Endocrine …, 2024 - academic.oup.com
Kisspeptin (KP) and neurokinin B (NKB) are neuropeptides that govern the reproductive
endocrine axis through regulating hypothalamic gonadotropin-releasing hormone (GnRH) …